Zim Laboratories (NSE:ZIMLAB) Cyclically Adjusted Revenue per Share: ₹82.57 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
82 GF Score
Price ₹118.04
GF Value ₹112.47
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Zim Laboratories Cyclically Adjusted Revenue per Share?

Zim Laboratories NSE:ZIMLAB -0.60% 82 Cyclically Adjusted Revenue per Share is ₹82.57 as of Jun. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 82/100 and a GF Value™ of ₹112.47 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zim Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹17.585. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹82.57 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-19), Zim Laboratories's current stock price is ₹118.04. Zim Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹82.57. Zim Laboratories's Cyclically Adjusted PS Ratio of today is 1.43.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zim Laboratories was 1.52. The lowest was 1.32. And the median was 1.38.


Zim Laboratories  (NSE:ZIMLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zim Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=118.04/82.57
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zim Laboratories was 1.52. The lowest was 1.32. And the median was 1.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zim Laboratories Cyclically Adjusted Revenue per Share Related Terms


Zim Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Cyclically Adjusted Revenue per Share Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zim Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 82.57

NSE:ZIMLAB vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:ZIMLAB
82GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zim Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.585/167.3573*167.3573
=17.585

Current CPI (Jun. 2026) = 167.3573.

Zim Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201706 13.052 107.109 20.394
201709 12.919 109.021 19.832
201712 15.437 109.404 23.614
201803 13.277 109.786 20.239
201806 14.606 111.317 21.959
201809 14.745 115.142 21.432
201812 20.141 115.142 29.275
201903 17.598 118.202 24.916
201906 12.988 120.880 17.982
201909 13.733 123.175 18.659
201912 15.101 126.235 20.020
202003 10.607 124.705 14.235
202006 14.464 127.000 19.060
202009 17.929 130.118 23.060
202012 15.458 130.889 19.765
202103 12.069 131.771 15.328
202106 13.603 134.084 16.979
202109 15.849 135.847 19.525
202112 17.885 138.161 21.665
202203 20.634 138.822 24.875
202206 19.098 142.347 22.453
202209 20.428 144.661 23.633
202212 20.651 145.763 23.710
202303 19.615 146.865 22.352
202306 14.881 150.280 16.572
202309 17.581 151.492 19.422
202312 19.723 152.924 21.584
202403 21.746 153.035 23.781
202406 16.396 155.789 17.614
202409 18.960 157.882 20.098
202412 19.744 158.323 20.871
202503 22.483 157.552 23.882
202506 14.543 159.755 15.235
202509 18.804 162.289 19.391
202512 22.238 163.281 22.793
202603 21.394 164.272 21.796
202606 17.585 167.357 17.585

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹82.57 mean?
Zim Laboratories (NSE:ZIMLAB) has a Cyclically Adjusted Revenue per Share of ₹82.57 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zim Laboratories and its competitors.
Is Zim Laboratories' Cyclically Adjusted Revenue per Share too high?
Zim Laboratories' current Cyclically Adjusted Revenue per Share is ₹82.57. Overall, Zim Laboratories has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS?
Zim Laboratories' Cyclically Adjusted Revenue per Share of ₹82.57 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zim Laboratories and its competitors. Zim Laboratories's current Cyclically Adjusted Revenue per Share is ₹82.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹112.47, compared to a current price of ₹118.04 — trading 5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹82.57. Zim Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Cyclically Adjusted Revenue per Share is ₹82.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹118.04 is trading 5% above its estimated GF Value™ of ₹112.47. GuruFocus considers Zim Laboratories to be Fairly Valued.

Key valuation signals for NSE:ZIMLAB:

  • Cyclically Adjusted Revenue per Share: ₹82.57
  • GF Value™: ₹112.47 vs. price of ₹118.04 (5% above fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
82GF Score

Get the complete analysis for NSE:ZIMLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹118.04
Price
₹112.47
GF Value